Published in Drug Week, September 6th, 2002
That Synthroid has received FDA approval is welcomed news for the members of the American Association of Clinical Endocrinologists (AACE) and the patients they treat.
In June 2001, the FDA notified Abbott Laboratories, makers of Synthroid that either a new drug application (NDA) must be filed or that evidence must be submitted to show that the product is not a new drug and is generally recognized as safe and effective. At this time AACE encouraged patients to not switch medications unless warranted by their...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.